Retatrutide Phase 2 NEJM Trial Results: What the 48-Week Data Showed
The Phase 2 NEJM trial of retatrutide reported up to 24.2% mean weight reduction at 48 weeks. What the trial measured, what it found, and what its limitations are — referenced to the published paper.













